KALV News and Press, KalVista Pharmaceuticals Inc. From 12/07/23

2023-12-07 06:57:34 ET More on KalVista Pharmaceticals KalVista's Sebetralstat: A Pill Worth Swallowing In HAE Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financial information for KalVis...

- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial - - Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 - KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on ...

– Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines – – Global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) may be greater than previously realized ȁ...

- Study completion activities underway; topline data expected early 2024 – - Largest-ever HAE clinical trial meets on-treatment attack target – - NDA submission remains on track for first half 2024 – KalVista Pharmaceuticals, Inc . (NASDAQ: KAL...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the Americ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks ...

2023-10-01 00:05:36 ET Summary KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista has a cash runway of about 14 months, but rising G&...

2023-09-07 06:32:03 ET More on KalVista Pharmaceticals Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financial information for KalVista Pharmaceticals For further details see: KalVista ...

- Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 - - Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval - KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharma...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting t...